Skip to main content

PUMA BIOTECHNOLOGY, INC.

For the period ended Jun 18, 2024. Filed Apr 26, 2024.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Jun 18, 2024 · Filed Apr 26, 2024

Use the contents to explore the available documents and sections.

PBYI$8.25-15.6%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Summary of Potential Payments

The following table summarizes the payments that would have been made to Messrs. Auerbach, Ludwig and Nougues upon the occurrence of a qualifying termination of employment (whether or not in connection with a change in control), assuming that the executive’s termination of employment with our Company occurred on December 31, 2023. Amounts shown do not include (i) accrued but unpaid salary through the date of termination, and (ii) other benefits earned or accrued by the executive during employment that are available to all salaried employees, such as accrued vacation. In addition, the following table does not include our other Named Executive Officers because they would not be entitled to any payments and/or benefits pursuant to any plan or agreement upon a termination and/or change in control occurring on December 31, 2023.

The following table also assumes that a successor corporation would assume or provide substitute equity awards in a change in control.

Name · Termination Without Cause or With Good Reason (Not in Connection with Change in Control) ($) · Termination Without Cause or With Good Reason (In Connection with Change in Control) ($)
Alan H. Auerbach
Cash Severance (1)2,019,1034,038,207
Continued Health Benefits18,99818,998
Acceleration of Equity Awards—1,016,859(2)
280G Excise Tax Gross-Up——(3)
Total2,038,1015,074,064
Maximo F. Nougues
Cash Severance515,521515,521
Continued Health Benefits39,45339,453
Acceleration of Equity Awards—342,134(2)
Total554,974897,108
Jeff J. Ludwig
Cash Severance (1)835,195835,195
Continued Health Benefits39,45339,453
Acceleration of Equity Awards—313,804(2)
Total874,6481,188,452
(1)In accordance with the terms of their respective agreements, Mr. Auerbach’s and Mr. Ludwig’s cash severance includes the maximum award amount for Mr. Auerbach, and target award amount for Mr. Ludwig, payable under our short-term incentive compensation program for the year of termination.
(2)Represents the sum of the values attributable to the accelerated vesting of the unvested portion of all outstanding stock options and RSUs held by the executive officers as of December 31, 2023. The value of the accelerated equity awards was calculated based on the closing price of our common stock on December 29, 2023 (the last trading day of the year) of $4.33 per share.
(3)No gross-up for excise taxes would be payable to Mr. Auerbach, or adjustments to his severance amounts, under his employment agreement if he had been terminated in connection with a change in control on December 31, 2023.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.